Newcastle disease virus (NDV): Brief history of its oncolytic strains

Journal of Clinical Virology

Volumn 16, Issue 1, 2000, Pages 1-15

  Sinkovics, Joseph G ^a,b   Horvath, Joseph C ^a,b  

^a ST JOSEPH HOSPITAL   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Oncolytic viruses; Viral oncolysates; Virus therapy of cancer

Indexed keywords

ONCOLYTIC VIRUS; VIRUS ONCOLYSATE;

DNA MODIFICATION; GENETIC SELECTION; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; KIDNEY CARCINOMA; MEASLES VIRUS; MELANOMA; MUMPS VIRUS; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRAIN DIFFERENCE; VIRUS VIRULENCE;

EID: 0033955837     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(99)00072-4     Document Type: Article

References (142)

1. Ackermann W., Kurtz H. A new host-virus system. Proc. Soc. Exp. Biol. Med. 81:1952;421-423.
2. Adams R.W., Pierce A.M. An electron microscopic study of incomplete virus formation. Infection of Ehrlich's ascites tumor cells with "chick embryo-adapted" Newcastle disease virus (NDV). J. Exp. Med. 106:1957;617-625.
3. Ahlert T., Schirrmacher V. Isolation of a human melanoma adapted Newcastle disease virus mutant with highly selective replication patterns. Cancer Res. 50:1990;5962-5968.
4. Asada T. Treatment of human cancer with mumps virus. Cancer. 34:1974;1907-1928.
5. Ballagi-Pordany A., Wehmann E., Herczeg J., Belak S., Lomniczi B. Identification and grouping of Newcastle disease virus strains by restriction site analysis of a region from the F gene. Arch. Virol. 141:1996;243-261.
6. Basedovsky H.O., delRey A. Mechanism of virus-induced stimulation of the hypothalamus-pituitary-adrenal axis. J. Steroid. Biochem. 34:1989;235-239.
7. + cell repertoire. Mol. Med. 4:1998;783-794.
8. Bauerle P.A., Baltimore D. NFκB: ten years after. Cell. 87:1996;13-20.
9. Berencsi K., Beladi I., Juhasz A. Interferon production and immunosuppression in NDV infected hamsters. Zschr. Immunitätsforsch. Exp. Klin. Immunol. 147:1974;441-448.
10. Bluming A.Z., Ziegler J.L. Regression of Burkitt's lymphoma in association with measles infection. Lancet. ii:1971;105-106.
11. Carr J., Mackie R.M. Point mutation in the N-ras oncogene in malignant melanoma and congenital naevi. Br. J. Dermatol. 131:1994;72-77.
12. Caruso C., Palmieri P., Dieli F. et al. Depression of contact sensitivity to oxazolone by the paramyxovirus of Newcastle disease. Impairment by infectious virus of effector T cells which mediate the response to contactant. Int. Arch. Allergy Appl. Immunol. 66:1981;91-99.
13. Cassel W.A. Multiplication of influenza virus in Ehrlich ascites carcinoma. Cancer Res. 17:1957;618-622.
14. Cassel W.A., Garrett R.E. Newcastle disease virus as an antineoplastic agent. Cancer. 18:1965;863-868.
15. Cassel W.A., Garrett R.E. Tumor immunity after viral oncolysis. J. Bacteriol. 92:1966;792.
16. Cassel W.A., Garrett R.E. Relationship between viral neurotropism and oncolysis. Cancer. 20:1967;433-439.
17. Cassel W.A., Murray D.R. A ten year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med. Oncol. Tumor Pharmacother. 9:1992;169-171.
18. Cassel W.A., Murray D.R., Phillips H.S. A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer. 52:1983;856-860.
19. Chambers P., Millar N.S., Bigham R.W., Emmerson P.T. Molecular cloning of complementary DNA to Newcastle disease virus and nucleotide sequence analysis of the junction between the genes encoding the hemagglutinin-neuraminidase and the large protein. J. Gen. Virol. 67:1986;475-486.
20. Coffey M.C., Strong J.E., Forsyth P.A., Lee P.W.K. Reovirus therapy of tumors with activated ras pathway. Science. 282:1998;1332-1334.
21. Coleman N.A., Peeples M.E. The matrix protein of Newcastle disease virus localizes to the nucleus via a bipartate nuclear localization signal. Virology. 195:1993;596-607.
22. Coukos G., Makrigiannakis A., Kang E.H. et al. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin. Cancer Res. 5:1999;1523-1537.
23. Csatary L.K., Moss R.W., Beuth J., Töröcsik B., Szeberenyi J., Bakacs T. Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Anticancer Res. 19:1998;635-638.
24. Daskalakis S., Menke J., Stripp B., Stone H. Nucleotide sequence of the phosphoprotein (P) gene of Newcastle disease virus (strain Beaudette C). Nucleic Acid Res. 20:1992;616.
25. DeLeeuw O., Peeters B. Complete nucleotide sequence of Newcastle disease virus: evidence for the existence of a new genus within the subfamily Paramyxovirinae. J. Gen. Virol. 80:1999;131-136.
26. Deling Y.N., Mufson A., Wang R., Shi Y. Fas-mediated cell death promoted by opioids. Nature. 397:1999;218.
27. Deng R., Wang Z., Mahon P.J., Marinello M., Mirza A., Iorio R.M. Mutations in the Newcastle disease virus hemagglutinin-neuraminidase protein that interfere with its ability to interact with the homologous F protein in the promotion of fusion. Virology. 253:1999;43-54.
28. Dieli F., Abrignani S., Lio D., Salerno A. Role of macrophages in bypassing the inhibitory activity of Newcastle disease virus on the T-suppressor-cell circuit which regulates contact sensitivity to picryl chloride. Cell Immunol. 111:1988;332-340.
29. Doyle T.M. A hitherto unrecorded disease of fowl due to a filter-passing virus. J. Comp. Pathol. 40:1927;144-169.
30. Dunn A.J., Vickers S.L. Neurochemical and neuroendocrine responses to Newcastle disease virus administration in mice. Brain Res. 645:1994;103-112.
31. Dunn S.M., Coles L.S., Lang R.K., Gerondakis S., Vadas M.A., Shannon M.F. Requirement for nuclear factor (NF)κBp65 and NF-interleukin-6 binding elements in the tumor necrosis factor response region of the granulocyte colony-stimulating factor promoter. Blood. 83:1994;2469-2479.
32. Editorial. Suppressive effect of Newcastle disease virus on primary and secondary immune responses of hamsters. Acta Virol 1977;21:296-300.
33. Everman J.F., Burnstein T. Immune enhancement of the tumorigenicity of hamster brain cells persistently infected with measles virus. Int. J. Cancer. 16:1975;861-869.
34. Ferdats A., Meisele O, Bruvere R, Rupais A, Muceniece A. Rationale for melanoma biotherapy by echovirus tumor vaccines. Abstract Book, 17th International Cancer Congress. Rio de Janeiro, Brazil, August 1998, p. 46, No. 179.
35. Flanagan A.D., Love R., Tesar W. Propagation of Newcastle disease virus in Ehrlich ascites cells in vitro and in vivo. Proc. Soc. Biol. Med. 90:1955;82-86.
36. Freytag S.O., Rogulski K.R., Paielli D.L., Gilbert J.D., Kim J.H. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther. 9:1998;1323-1333.
37. Fugier-Vivier I., Servet-Delprat C., Rivailler P., Rissoan M.C., Lin Y.J., Rabourdin-Combe C. Measles virus suppresses cell-mediated immunity by interfering with the survival and function of dendritic and T cells. J. Exp. Med. 186:1997;813-823.
38. Fujii Y., Sakaguchi T., Kiyotani K., Yoshida T. Comparison of substrate specificities against the fusion glycoprotein of virulent Newcastle disease virus between a chick embryo fibroblast processing protease and mammalian subtilisin like proteases. Microbiol. Immunol. 43:1999;133-140.
39. Furukawa K., Lotzova E., Freedman R.S., Bowen J.B., Edwards C.L., Wharton J.T. Effect of virus-modified tumor cell extracts, autologous mononuclear cell infusions and interleukin-2 on oncolytic activity of effector cells of patients with advanced ovarian cancer. Cancer Immunol. Immunother. 30:1989;126-132.
40. Garcia D.M., Fulling K.H. Juvenile pilocytic astrocytoma of the cerebrum in adults. A distinctive neoplasm with favorable prognosis. J. Neurosurg. 63:1985;382-386.
41. Gnann J.W. Mumps. Richman D.D., Whitley R.J., Hayden F.G. Clinical Virology. 1997;863-877 Churchill Livingstone, London.
42. Granoff A., Hirst G.K. Experimental production of combination forms of virus. IV. Mixed influenza A-Newcastle disease virus infection. Proc. Soc. Exp. Biol. Med. 86:1954;84-88.
43. McD. Hammon W., Yohn D.S., Casto B.C., Atkinson R.W. Oncolytic potentials of nonhuman viruses for human cancer: effects of twenty-four viruses on human cancer cell lines. J. Natl. Cancer Inst. 31:1963;329-345.
44. Harbour D.V., Galin F.S., Hughes T.K., Smith E.M., Blalock J.E. Role of leukocyte-derived pro-opiomelanocortin peptides in endotoxic shock. Circ. Shock. 35:1991;181-191.
45. Heise C.C., Williams A.M., Xue S., Propst M., Kirn D.H. Intravenous administration of ONYX-015 a selectively replicating adenovirus induces antitumor efficacy. Cancer Res. 59:1999;2623-2628.
46. Hersey P., Edwards A., D'Alessandro G., McDonald M. Phase II study of vaccinia melanoma cell lysates as adjuvant to surgical treatment of stage II melanoma. Cancer Immunol. Immunother. 22:1986;221-231.
47. Horvath J., Horak A., Sinkovics J.G. Comparison of oncolytic Newcastle disease virus strains. Proc. 86th Annu. Meet. Am. Assoc. Cancer Res. 36:1995;439. No. 2619.
48. Horvath J.C., Horak A., Sinkovics J.G., Pritchard M., Pendleton S., Horvath E. Cancer vaccines with emphasis on a viral oncolysate melanoma vaccine. Acta Microbiol. Immunol. Hung. 46:1999;1-20.
49. Jayawardane C.W., Spradbrow B.B. Mucosal immunity in chickens vaccinated with the V4 strain of Newcastle disease virus. Vet. Microbiol. 46:1995;69-77.
50. Jiveskog S., Ragnarsson-Olding B., Platz A., Ringborg U. N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J. Invest. Dermatol. 111:1998;757-761.
51. Kaiserlian D., Grosjean I., Caux C. Infection of human dendritic cells by measles virus induces immune suppression. Adv. Exp. Med. Biol. 417:1997;421-423.
52. Kay H.D., Thota H., Sinkovics J.G. A comparative study on in vitro cytotoxic reactions of lymphocytes from normal donors and patients with sarcomas to cultured tumor cells. Clin. Immunol. Immunopathol. 5:1976;218-234.
53. Kenney S., Pagano J.S. Viruses as oncolytic agents: a new age for "therapeutic" viruses. J. Natl. Cancer Inst. 36:1994;1185-1186.
54. Kingsbury DW. Paramyxoviridae and their replication. In: Fields BN, Knipe DM et al., editors. Fields Virology, 2nd ed. Raven Press: New York, 1990:945-962.
55. Kirchner H.H., Anton P., Atzpodien J. Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines. World J. Urol. 13:1995;171-173.
56. Kooby D.A., Carew J.F., Halterman M.W. et al. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J. 13:1999;1325-1334.
57. Koprowski H., Love R., Koprowska I. Viruses and tumor growth. Tex. Rep. Biol. Med. 15:1957;111-128.
58. Krishnamurthy S., Samal S.K. Nucleotide sequences of the trailer, nucleocapsid protein gene and intergenic regions of Newcastle virus strain Beaudette C and completion of the entire genome sequence. J. Gen. Virol. 10:1998;2419-2424.
59. Kunishige I., Samejima Y., Shiki Y. et al. Suicide gene therapy for human uterine adenocarcinoma cells using herpes simplex virus thymidine kinase. Gynecol. Oncol. 72:1999;16-25.
60. Lam K.M., Vasconcelos A.C. Newcastle disease virus-induced apoptosis of chicken peripheral lymphocytes. Vet. Immunol. Immunopathol. 44:1994;45-56.
61. Lam K.M., Vasconcelos A.C., Bickford A.A. Apoptosis as a cause of death in chicken embryos inoculated with Newcastle disease virus. Microb. Pathog. 19:1995;169-174.
62. Lawton P., Karimi Z., Mancinelli L., Seto J.T. Persistent infections with Sendai virus and Newcastle disease virus. Arch. Virol. 80:1980;225-233.
63. Leisti E.L., Pyhtinen J., Poyhonen M. Spontaneous decrease of a pilocytic astrocytoma in neurofibromatosis type I. Am. J. Neuroradiol. 17:1996;1691-1694.
64. Lengauer C., Kinzler K.W., Vogelstein B. Genetic instabilities in human cancers. Nature. 396:1998;643-649.
65. Levaditi C., Haber P. Affinité du virus de la peste aviaire pour les cellules neoplastiques. Compt. Rend. Soc. Biol. 202:1936;2018-2020.
66. Levaditi C., Nicolau S. Vaccine et neoplasmes. Ann. Inst. Pasteur. 37:1923;1-3.
67. Li Z., Zergel T., Razvi F., Morrison T. Effect of cleavage mutants on syncytium formation directed by the wild-type fusion protein of Newcastle disease virus. J. Virol. 72:1998;3789-3795.
68. Lindenmann J., Klein P. Immunological aspects of viral oncolysis. Rec. Res. Cancer Res. 9:1967;1-84.
69. Lomniczi B., Wehmann E., Herczeg J. et al. Newcastle disease outbreaks in recent years in Western Europe were caused by an old (VI) and a novel (VII) genotype. Arch. Virol. 143:1998;49-64.
70. Lorence R.M., Katubig B.B., Reichard K.W. et al. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res. 54:1994a;6017-6021.
71. Lorence R.M., Reichard K.W., Katubig B.B. et al. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus. J. Nat. Cancer Inst. 86:1994b;1228-1233.
72. Mazumder S., Nath I., Dhar M.M. Immunomodulation of human T cell responses with receptor selective enkephalins. Immunol. Lett. 35:1993;33-38.
73. McGinnes L., Sergel T., Morrison T. Mutations in the transmembrane domain of the HN protein of Newcastle disease virus affect the structure and activity of the protein. Virology. 196:1993;101-110.
74. Millar N.S., Chambers P., Emmerson P.T. Nucleotide sequence of the fusion and haemagglutinin-neuraminidase glycoprotein genes of Newcastle disease virus strain Ulster: molecular basis for variations in pathogenicity between strains. J. Gen. Virol. 69:1988;613-620.
75. Moore A.E. Viruses with oncolytic properties and their adaptation to tumors. Ann. NY Acad. Sci. 54:1952;945-952.
76. Murphy FA. Virus taxonomy. In: Fields BN, Knipe DM and Howley PM, editors. Fields Virology, 3rd ed, Lippincott, Philadelphia, PA, 1996:15.
77. Nagai Y. Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding. Rev. Med. Virol. 9:1999;83-99.
78. Nagai Y., Hamaguchi M., Toyoda T. Molecular biology of Newcastle disease virus. Prog. Vet. Microbiol. Immunol. 5:1989;16-64.
79. Nagy E., Derbyshire J.B., Dobos P., Krell P.J. Cloning and expression of NDV hemagglutinin-neuraminidase cDNA in a Baculovirus expression vector system. Virology. 176:1990;426-438.
80. Neustock P., Kruse A., Bein G., Nisser S., Kirchner H. Failure to detect type 1 interferon production in human umbilical cord vein endothelial cells. J. Interferon Cytokine Res. 15:1995;129-135.
81. Newman W., Southam C.M. Virus treatment of advanced cancer. Cancer. 7:1954;106-118.
82. Okamoto K., Ohgimoto S., Nishio M. et al. Paramyxovirus-induced syncytium cell formation is suppressed by a dominant negative fusion regulatory protein-1 (FRP-1)/CD98 mutated construct. J. Gen. Virol. 78:1997;775-783.
83. Peeters B.P., deLeeuw O.S., Koch G., Gielkens A.L. Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J. Virol. 73:1999;5001-5009.
84. Peli J., Schroter M., Rudaz C. et al. Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas. EMBO J. 18:1999;1824-1831.
85. Peterson P.K., Molitor T.W., Chao C.C. The opioid-cytokine connection. J. Neuroimmunol. 83:1998;63-69.
86. Phillips R.J., Samon A.C.R., Emmerson P.T. Nucleotide sequence of the 5′-terminus of Newcastle disease virus and assembly of the complete genomic sequence: agreement with the "rule of six" Arch. Virol. 143:1998;1993-2002.
87. Pokric B, Sladic D, Juros S, Cajavecs. Application of the immune complex for immune protection against viral disease. Vaccine 1993;11,655-659.
88. Polack F.P., Auwaerter P.G., Lee S.-H., Nousori H.C., Valsamakis A., Lieferman K.M. Production of atypical measles in rhesus macaques: evidence for disease modified by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat. Med. 5:1999;629-634.
89. Reichard K.W., Lorence R.M., Cascino C.J. et al. Newcastle disease virus selectively kills human tumor cells. J. Surg. Res. 52:1992;448-453.
90. Rein T., Schreck R., Willenbrink W., Neubert W.J., Zorbas H., Bauerle P.A. Conserved high-affinity NF-kappa B binding site in the interferon regulatory factor-1 promoter is not occupied by NF-kappa B in vivo and is transcriptionally inactive. J. Inflamm. 45:1995;269-282.
91. Reitter J.N., Sergel T., Morrison T.G. Mutational analysis of the leucine zipper motif in the Newcastle disease virus fusion protein. J. Virol. 69:1995;5995-6004.
92. Rommelaere J., Tattersal P. Oncosuppression by parvoviruses. In: Tjissin P, editor. Handbook of Parvoviruses. CRC Press, Boca Raton FL, 1990:41-58.
93. Rood P.A., Lorence R.M., Kelley K.W. Serum protease inhibitor abrogration of Newcastle disease virus enhancement of cytolysis by recombinant tumor necrosis factor alpha and beta. J. Natl. Cancer Inst. 82:1990;213-217.
94. Sakaguchi T., Fujii Y., Kiyotani K., Yoshida T. Correlation of proteolytic cleavage of F protein precursors in paramyxoviruses with expression of the fur, PACE4 and PC6 genes in mammalian cells. J. Gen. Virol. 75:1994;2821-2827.
95. Scanlon D.B., Corino G.L., Shiell B.J. et al. Pathotyping isolates of Newcastle disease virus using antipeptide antibodies to pathotype-specific regions of their fusion and hemagglutinin-neuraminidase proteins. Arch. Virol. 144:1999;55-72.
96. Schirrmacher V., Haas C., Bonifer R., Ertel C. Virus potentiation of tumor vaccine T cell stimulatory capacity requires cell surface binding but not infection. Clin. Cancer Res. 3:1994;1135-1148.
97. Schirrmacher V., Ahlert T., Pröbstle T. et al. Immunization with virus-modified tumor cells. Semin. Oncol. 25:1998;677-696.
98. Schirrmacher V., Haas C., Bonifer R., Ahlert T., Gerhards R., Ertel C. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene. Therapy. 6:1999;63-73.
99. Schirrmacher V., Jurianz K., Roth C., Griesbach A., Bonifer R., Zawatzky R. Tumor stimulator cell modification by infection with Newcastle disease virus: analysis of effects and mechanisms in MLTC-CML cultures. Int. J. Oncol. 14:1999;205-215.
100. Seal B.S. Analysis of matrix protein gene nucleotide sequence diversity among Newcastle disease virus isolates demonstrate that recent disease outbreaks are caused by viruses of psittacine origin. Virus Genes. 11:1995;217-224.
101. Seal B.S., King D.J., Bennett J.D. Characterization of Newcastle disease virus isolates by reverse transcription PCR coupled to direct nucleotide sequencing and development of sequence database for pathotype prediction and molecular epidemiological analysis. J. Clin. Microbiol. 33:1995;2624-2630.
102. Shimizu Y., Hasumi K., Okadaira Y., Yaminishi K., Takahashi M. Immunotherapy of advanced gynecologic cancer patients utilizing mumps virus. Cancer Detect. Prev. 12:1988;487-495.
103. Sinkovics J. Die Grundlagen der Virusforschung. 1956;98-103 Ungarischen Akademie, Budapest, Hungary.
104. Sinkovics J. Enhancement of carcinostatic activity of Newcastle disease virus (NDV) associated with adaptation to suckling mouse brain. Bacteriol. Proc. 96:1957;M108.
105. Sinkovics J. The human pathogenicity of the Newcastle disease virus and its relation to the mumps, fowl plague and influenza viruses. Arch. Ges. Virusforsch. 7:1957;242-257.
106. Sinkovics J. Studies on the biological characteristics of the Newcastle disease virus (NDV) adapted to the brain of newborn mice. Arch. Ges. Virusforsch. 7:1957;403-411.
107. Sinkovics J. Interactions of the Newcastle disease virus with mouse tissues. Arch. Ges. Virusforsch. 10:1960;103-125.
108. Sinkovics J.G. Monitoring in vitro of cell-mediated immune reactions to tumors. Methods Cancer Res. 8:1973;107-175.
109. Sinkovics J. Oncolytic viruses. Harris J.E., Sinkovics J.G. The Immunology of Malignant Disease. 1976;180-182 CV Mosby, St Louis.
110. Sinkovics J.G. Suppressor cells in human malignant disease. Br. J. Med. 1:1976;1072-1073.
111. Sinkovics JG. Oncolytic viruses in selected patients with cancer. In: Research Report, University Texas MD Anderson Hospital, Houston, TX, University Texas Printing Division, Austin, TX, 1968-70:348-349; 1972:488-490; 1974:473-474; 1976:533-536.
112. Sinkovics JG. Oncolytic viruses in selected patients with cancer. In: Research Report, University Texas MD Anderson Hospital, Houston, TX, University Texas Printing Division, Austin, TX, 1968-70:348-349; 1972:488-490; 1974:473-474; 1976:533-536.
113. Sinkovics JG. Oncolytic viruses in selected patients with cancer. In: Research Report, University Texas MD Anderson Hospital, Houston, TX, University Texas Printing Division, Austin, TX, 1968-70:348-349; 1972:488-490; 1974:473-474; 1976:533-536.
114. Sinkovics JG. Oncolytic viruses in selected patients with cancer. In: Research Report, University Texas MD Anderson Hospital, Houston, TX, University Texas Printing Division, Austin, TX, 1968-70:348-349; 1972:488-490; 1974:473-474; 1976:533-536.
115. Sinkovics J.G. Viral oncolysates as human tumor vaccines. Int. Rev. Immunol. 7:1991;259-287.
116. Sinkovics J., Horvath J. New developments in the virus therapy of cancer: a historical review. Intervirology. 36:1993;193-214.
117. Sinkovics J.G., Horvath J. Can virus therapy of human cancer be improved by apoptosis induction? Med. Hypotheses. 44:1995;359-368.
118. Sinkovics J.G., Horvath J.C. Kaposi's sarcoma: breeding ground of Herpesviridae. A tour de force over viral evolution. Int. J. Oncol. 14:1999;615-646.
119. Sinkovics J.G., Howe C.D. Superinfection of tumors with viruses. Experientia. 25:1969;733-734.
120. Sinkovics J.G., Kay H.D., Thota H. Evaluation of chemoimmunotherapy regimens by in vitro lymphocyte cytotoxicity directed to cultured human tumor cells. Bibl. Haematol. 43:1976;281-284.
121. Southam C.M., Moore A.E. Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus. Cancer. 5:1952;1025-1034.
122. Stitz L., Huang R.T., Hengartner H., Rott R., Zinkernagel M. Cytotoxic T cell lysis of target cells fused with liposomes containing influenza virus haemagglutinin and neuraminidase. J. Gen. Virol. 66:1985;1333-1339.
123. Stone-Hulslander J., Morrison T.G. Detection of an interaction between the HN and F proteins in Newcastle disease virus-infected cells. J. Virol. 71:1997;6287-6295.
124. Szeri I., Anderlik P., Banos Z., Barna Z. Effect of microbiologic immunomodulants on the course of LCMV infection in old mice with thymus involution. Acta Microbiol. Hung. 39:1992;13-19.
125. Ten R.M., Blank V., LeBail O., Kourilsky P., Israel A. Two factors IRF-1 and KBF1/NFκB cooperate during induction of MHC class I gene expression by interferon alpha beta or Newcastle disease virus. Compt. Rend. Acad. Sci. 316:1993;496-501.
126. Thiele C.J., Reynolds P.C., Israel M.A. Decreased expression of N-myc precedes retinoic acid induced phenotypic differentiation of neuroblastoma. Nature. 313:1985;404-406.
127. Toda M., Rabkin S.D., Kojima H., Martuza R.L. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum. Gene Ther. 10:1999;385-393.
128. Toyoda T., Sakaguchi T., Imai K. et al. Structural comparison of the cleavage-activation site of the fusion glycoprotein between virulent and avirulent strains of Newcastle disease virus. Virology. 158:1987;242-247.
129. Toyoda T., Sakaguchi T., Hirota H. et al. Newcastle disease virus evolution. II. Lack of gene recombination in generating virulent and avirulent strains. Virology. 169:1989;273-282.
130. Tzadok-David Y., Metzkin-Eizenberg M., Zakay-Rones Z. The effect of a mesogenic and a lentogenic Newcastle disease virus strain on Burkitt lymphoma Daudi cells. J. Cancer Res. Clin. Oncol. 121:1995;169-174.
131. Umino V., Kohama T., Kohase M., Sugiura A., Klenk H.D., Rott R. Protective effect of antibodies to two viral envelope glycoproteins on lethal infection with Newcastle disease virus. Arch. Virol. 94:1987;97-107.
132. Vanguri P., Farber J.M. IFN and virus-inducible expression of an immediate early gene crg2/IP-10 and a delayed gene I-A alpha crg2/IP-10 in astrocytes and microglia. J. Immunol. 152:1994;1411-1418.
133. VonHoegen P., Weber E., Schirrmacher V. Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response. Eur. J. Immunol. 18:1988;1159-1166.
134. Wallack M.K., Sivanandham M., Balch C.M. et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III randomized double-blind multicenter vaccinia melanoma oncolysate trial. J. Am. Coll. Surg. 187:1998;69-79.
135. Wang C., Raghu G., Morrison T., Peeples M.E. Intracellular processing of the paramyxovirus F protein: critical role of the predicted amphipathic alpha helix adjacent to the fusion domain. J. Virol. 66:1992;4161-4169.
136. Wertz K., Buttner M., Mayr A., Kaaden O.R. More than one component of the Newcastle disease virus particle is capable of interferon induction. Vet. Microbiol. 39:1994;299-311.
137. Westly H.J., Kleiss A.J., Kelley K.W., Wong P.K., Yuen P.H. Newcastle disease virus-infected splenocytes express the pro-opiomelanocortin gene. J. Exp. Med. 163:1986;1589-1594.
138. Yang C.Y., Shich H.K., Lin Y.L., Chang P.C. Newcastle disease virus isolated from recent outbreaks in Taiwan phylogenetically related to viruses (genotype VII) from recent outbreaks in Western Europe. Avian Dis. 43:1999;125-130.
139. Ying H., Zaks T.Z., Wang R.F. et al. Cancer therapy using a self-replicating RNA vaccine. Nat. Med. 5:1999;823-827.
140. Yohn D.S., Hammon W.M., Atchinson R.W., Casto B.C. Oncolytic potentials of nonhuman viruses for human cancer. II. Effects of five viruses on heterotransplantable tumors. J. Natl. Cancer Inst. 41:1968;523-529.
141. Yu Z.F., Lin M.F., Wang B.C., Lin X.Y., Lin X.H. Chemoimmunotherapy versus chemotherapy in acute leukemia remission induction. Chin. Med. J. 94:1981;31-34.
142. Zorn U., Dallmann I., Grosse J., Kirchner H., Poliwoda H., Atzpodien J. Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus. Cancer Biother. 9:1994;225-235.